Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.
about
Twenty two cases of canine neural angiostronglyosis in eastern Australia (2002-2005) and a review of the literatureFrequency of appropriate and inappropriate presentation and analysis methods of ordered categorical data in the veterinary dermatology literature from January 2003 to June 2006.Analytical validation of a quantitative reverse transcriptase polymerase chain reaction assay for evaluation of T-cell targeted immunosuppressive therapy in the dog.Oral cyclosporine treatment in dogs: a review of the literature.Bioequivalence study between two formulations of ciclosporin A (Cyclavance® oral solution and Atopica® soft capsules) following a single oral administration to dogsUnsuccessful cyclosporine plus prednisolone therapy for autoimmune meningoencephalitis in three dogs.Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.Ciclosporin 10 years on: indications and efficacy.Voluntary acceptance and consumption of two oral ciclosporin formulations in dogs: two randomised, controlled studiesTreatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011).The effect of ketoconazole on whole blood and skin ciclosporin concentrations in dogs.Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at -20°C and room temperature.Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.Pharmacodynamic monitoring of canine T-cell cytokine responses to oral cyclosporine.
P2860
Q27006520-F1D2F388-70B6-4A8F-A520-D6D10AC4876EQ31117695-E12013D3-C4B1-413C-B872-A424262BCE92Q33988773-9702A03B-F1E4-426B-AC4E-DB1A07B15C2DQ34392104-218F517E-A50F-4CD5-AE76-B05A1EF4096AQ35955166-76DE2672-705A-49E4-B409-FC17A41A6AACQ37618233-29F838D4-AAC4-439C-965F-CCD989D8440CQ38200540-AABF4742-C797-4485-A153-E4730667816DQ38200541-67A5501E-F5EC-486F-8CDB-D903FAE6D3A1Q41825444-933BC7A1-58A7-4F24-80E7-43DC3F7C344EQ44062351-F5A3CFA3-B676-42F5-91A0-5D5AD0C4072CQ44634059-3095F7C4-16DA-4886-A0FF-44AD6F66F4A1Q48158348-D3C0F67D-54FC-4D5A-BA98-6973F7D8C0A7Q48463862-E4B35A26-7E1D-4CBF-96BC-A27B86AEBD72Q51387488-6CEF3E9F-8BA9-41F5-9D93-651548966FBD
P2860
Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@en
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@nl
type
label
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@en
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@nl
prefLabel
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@en
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@nl
P2093
P2860
P1476
Cyclosporin A pharmacokinetics ...... of atopic dermatitis in dogs.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2885.2004.00587.X
P577
2004-08-01T00:00:00Z